Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients

The initiation of biological treatment was higher in patients with younger symptom onset, in patients with JIA comorbidity, and in patients with homozygous exon 10 or compound heterozygous exon 10 mutation. Gender, delay in diagnosis, comorbidities other than JIA, family history of FMF, amyloidosis or chronic kidney disease did not increase the initiation of biological treatment.